Results 151 to 160 of about 1,197 (187)

0868 Long-Term Safety and Effectiveness of Pitolisant Use in Adult Patients with Idiopathic Hypersomnia (IH)

Sleep
Pitolisant is being evaluated for use in adult patients with IH in two phase 3 clinical trials, a double-blind randomized withdrawal (DBRW) and an open-label extension (OLE). The present analyses focused on the safety and effectiveness of long-term
Y. Dauvilliers, D. Plante, Bruce C. Corser, C. Drake, Richard Bogan, Salvatore Insana, David Seiden, George Nomikos, Katie Wilmsen, Michelle Manuel, Kumar Budur, Jeffrey Dayno   +11 more
semanticscholar   +1 more source

Pitolisant Improves Depressive Symptoms in CPAP-Treated Patients with Obstructive Sleep Apnea and Severe Residual Sleepiness: First 12-Month Clinical Experience

CNS Drugs
Obstructive sleep apnea (OSA) is a chronic condition affecting almost one billion people worldwide associated with relevant morbidity and mortality.
Domenico Caratozzolo, G. Muscato, Pierpaolo Rizzo, Cristina Gangemi, Adriana Scionti, S. Mancuso, Carlo Vancheri, Lucia Spicuzza   +7 more
semanticscholar   +1 more source

0648 Phase 3 Randomized Placebo-Controlled Trial of Pitolisant for Excessive Daytime Sleepiness in Prader-Willi Syndrome

Sleep
Prader-Willi syndrome (PWS) is a genetic, neurodevelopmental disorder characterized by global hypothalamic dysfunction that results in a variety of symptoms including behavioral disturbance, hyperphagia, and excessive daytime sleepiness (EDS ...
Amee Revana, David Seiden, Krystle Davis Rapchak, A. Adee, Eric Bauer, Grant Runyan, George Nomikos   +6 more
semanticscholar   +1 more source

0631 Phase 2, Proof-of-Concept Study of Pitolisant in Prader-Willi Syndrome: Primary and Secondary Efficacy Analyses

Sleep
Prader-Willi Syndrome (PWS) is a complex genetic disorder with symptoms that include hyperphagia, behavioral disturbances, and excessive daytime sleepiness (EDS).
Amee Revana, R. Bhattacharjee, Jennifer Miller, P. Khanna, Ann Scheimann, Aaron Chidekel, Shawn E McCandless, A. R. Shelton, Haramandeep Singh, D. Norman, T. Patel, J. Maynard, Casey J Burg, Krystle Davis Rapchak, David Seiden   +14 more
semanticscholar   +1 more source

Pitolisant (Wakix) for Narcolepsy

JAMA, 2021
openaire   +4 more sources

Neuropsychiatry of Histaminergic Circuits: Potential Role of Novel H3 Receptor Selective Antagonist/Inverse Agonist Pitolisant in Prader-Willi Syndrome.

Psychopharmacology bulletin
Histamine and its receptors have been implicated in several neuropsychiatric conditions including Gilles de la Tourette syndrome, schizophrenia, attention deficit hyperactivity disorder, narcolepsy, Parkinson’s disease, Huntington’s disease, Alzheimer’s ...
Beatriz Freitas, T. Teodoro
semanticscholar   +1 more source

Antihistamine agents and pitolisant might be useful for anorexia nervosa

Medical Hypotheses, 2019
This hypothesis is that patients with anorexia nervosa (AN) demonstrate derangement in the histamine central nervous system. It might be possible to ameliorate these by careful use of histamine receptor antagonists targeting Histamine 1, 2, or 3 receptors. Histamine 3 receptors are exclusively present in the brain.
openaire   +2 more sources

Pitolisant

Reactions Weekly, 2022
openaire   +1 more source

Pharmacological modulation of wakefulness and extracellular hypothalamic histamine release in adult male mice using TAK-925, modafinil, pitolisant, MK-8133 and Lu AF11167.

Neuropharmacology
Histamine is a key regulator of wake and arousal, however its role in pharmacological modulation of wake is largely unknown. Specifically, whether histamine is always activated during pharmacologically induced wake promotion or even necessary for wake ...
C.G. Hviid, Gunnar Sørensen, B. R. Kornum, K. F. Herrik   +3 more
semanticscholar   +1 more source

Modafinil/pitolisant

Reactions Weekly, 2023
openaire   +1 more source